IO Biotech Announces Third Quarter Results for 2022
IO Biotech announced key developments in its clinical trials and financial performance for Q3 2022. The global Phase 3 trial of IO102-IO103 with KEYTRUDA® has seen a significant increase in site activations, from 19 to 55 over three months, indicating strong patient enrollment potential. The Phase 1/2 study reports a median overall survival of 46.8 months and a complete response rate of 50%. The company ended the quarter with $151.2 million in cash, ensuring funding for upcoming data readouts into mid-2024. However, net losses for the quarter increased to $16.1 million.
- Accelerated site activation for Phase 3 trial, boosting patient enrollment prospects.
- Q3 2022 reported median overall survival of 46.8 months and 50% complete response rate in Phase 1/2 study.
- Strong cash position of $151.2 million supports operations through mid-2024.
- Increased net loss for Q3 2022 to $16.1 million, up from $4.5 million in Q3 2021.
- Research and development expenses rose significantly to $10.1 million from $4.1 million year-over-year.
- Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company’s global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma
- Oral presentation and two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37thAnnual Meeting this week will provide an overview of the Phase 1/2 study (MM1636) with IO102-IO103 in combination with nivolumab for metastatic melanoma and discuss preclinical work on the next two candidates in the IO Biotech pipeline, which target the immunosuppressive effects of Arginase 1 (ARG1) and Transforming Growth Factor Beta 1 (TGFβ1)
- Results from a new October 2022 data cut for the MM1636 Phase 1/2 study with IO102-IO103 in combination with nivolumab for metastatic melanoma continue to be encouraging with median overall survival (mOS) at 46.8 months; median progression free survival (mPFS) at 22.5 months, and a complete response rate of
50%
- The company ended the third quarter with
$151.2 million in cash, which supports multiple expected data readouts into mid-2024
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ending September 30, 2022.
“During the last three months, we have made significant progress with the activation of clinical sites participating in our global Phase 3 combination trial of IOB102-IO103 with pembrolizumab as a potential first-line treatment in advanced melanoma,” said Mai-Britt Zocca, Ph.D., President and Chief Executive Officer of IO Biotech. “We ended October with 55 sites actively enrolling in study, compared to 19 actively enrolling sites at the end of July. We view the pace of site activation as a leading indicator of patient enrollment, and we are very pleased with our progress.”
Dr. Zocca continued, “Additionally, enrollment in our second ongoing clinical study, the Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab, is progressing nicely and we continue to expect to receive preliminary data in one indication this quarter with additional data in 2023. We believe that our T-win® platform―and its novel approach to activate naturally occurring T cells to target immunosuppressive mechanisms―has the potential to benefit patients in need of more treatment options and look forward to reporting our progress in the coming months.”
Highlights for Third Quarter 2022 and Recent Weeks
- An invited oral presentation and two poster presentations related to the company’s programs are being presented at the 2022 SITC Annual Meeting this week. See the following press release for more information, “IO Biotech ApS - IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.”
- Consistent with the earlier reported data, with an additional 12 months of patient follow-up, results from a new October 2022 data cut for the MM1636 Phase 1/2 study with IO102-IO103 in combination with nivolumab for metastatic melanoma continue to be encouraging. As of that data cut-off, 30 PD-1 naïve patients were enrolled with a median follow-up time of 31.7 months. Median overall survival (mOS) was reached at 46.8 months post first trial treatment, median progression free survival (mPFS) was 22.5 months, and
50% of patients (15/30) achieved a complete response (CR), or complete disappearance of their tumors. The overall response rate for the study was73.3% , as previously reported. Patients who were PD-1 refractory and enrolled in cohort B in this study had no response to therapy, which we believe shows that our vaccine works best in front-line metastatic melanoma patients, as we expected in this setting. - In the past three months, the company has accelerated the rate of clinical trial site activation in the global Phase 3 trial of IO102-IO103 in combination with pembrolizumab for front-line treatment of PD-1 naïve metastatic melanoma patients.
- In October 2022, the company named Amy Sullivan as Chief Financial Officer. Ms. Sullivan brings 30 years of experience building biotech companies to IO Biotech.
- In November 2022, the company entered into a fourth clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary. See the following press release for more information, “IO Biotech ApS - IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors.”
Third Quarter Financial Results
- Net loss for the three months ended September 30, 2022 was
$16.1 million , compared to$4.5 million for the quarter ended September 30, 2021. - Research and development expenses were
$10.1 million for the three months ended September 30, 2022, compared to$4.1 million for the three months ended September 30, 2021. The increase of$6.0 million was primarily related to an increase in preclinical studies and clinical trial-related activities for our IO102-IO103 product candidate, including the continued execution of our Phase 3 clinical trial, of$3.0 million , an increase in costs for chemistry, manufacturing and control, activities of$0.2 million , and an increase in personnel costs of$2.5 million primarily related to an increase in headcount and related recruiting costs. - General and administrative expenses were
$6.1 million for the three months ended September 30, 2022, compared to$2.9 million for the three months ended September 30, 2021. The increase of$3.2 million was primarily related to costs primarily associated with being a public company. - Other income, net was
$0.3 million for the three months ended September 30, 2022, compared to$2.6 million for the three months ended September 30, 2021. The decrease of$2.3 million was primarily due to the decrease in the fair value adjustments on the Company's preferred stock tranche obligations. - Cash and cash equivalents as of September 30, 2022, were
$151.2 million , compared to$211.5 million at December 31, 2021. During the third quarter 2022, the Company used cash, cash equivalents and restricted cash of$14.2 million from operating, investing and financing activities with an additional decrease of$4.8 million in cash due to the effects of foreign currency exchange rates. Cash on hand is expected to support operations through anticipated data readouts into mid-2024.
About the IOB-013/KN-D18 Clinical Trial
IOB-013/KN-D18 (ClinicalTrials.gov: NCT05155254) is an open label, randomized Phase 3 clinical trial being conducted in collaboration with Merck of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable or metastatic (advanced) melanoma. Target enrollment will be 300 patients from centers spread across Europe, Australia, and the United States. Biomarker analyses will also be conducted. IO Biotech will sponsor the Phase 3 trial and Merck will supply pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
About IOB-022/KN-D38 Clinical Trial
IOB-022/KN-D38 (ClinicalTrials.gov: NCT05077709) is a non-comparative, open label Phase 2 trial to investigate the safety and efficacy of IO102-IO103 in combination with pembrolizumab in each of the following first-line indications: non-small cell lung cancer, squamous cell carcinoma of the head and neck, and metastatic urothelial bladder cancer. The clinical trial will be sponsored by IO Biotech and conducted in collaboration with Merck. IO Biotech maintains global commercial rights to IO102-IO103.
About IO102-IO103
IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials, trials results and clinical site activation, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Company Contact:
Amy Sullivan
Chief Financial Officer
IO Biotech, Inc.
asu@iobiotech.com
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Media Contact:
Raena Mina, Ph.D.
LifeSci Communications
646-606-1438
rmina@lifescicomms.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
IO BIOTECH, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | $ | 10,145 | $ | 4,128 | $ | 32,676 | $ | 13,712 | ||||||||
| General and administrative | 6,101 | 2,914 | 18,740 | 6,127 | ||||||||||||
| Total operating expenses | 16,246 | 7,042 | 51,416 | 19,839 | ||||||||||||
| Loss from operations | (16,246 | ) | (7,042 | ) | (51,416 | ) | (19,839 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Currency exchange (loss) gain, net | (86 | ) | 17 | (392 | ) | 309 | ||||||||||
| Interest income | 457 | — | 631 | — | ||||||||||||
| Interest expense | (78 | ) | (67 | ) | (304 | ) | (210 | ) | ||||||||
| Fair value adjustments on preference shares tranche obligations | — | 2,630 | — | (26,830 | ) | |||||||||||
| Total other income (expense), net | 293 | 2,580 | (65 | ) | (26,731 | ) | ||||||||||
| Loss before income tax expense | (15,953 | ) | (4,462 | ) | (51,481 | ) | (46,570 | ) | ||||||||
| Income tax expense | 115 | — | 286 | — | ||||||||||||
| Net loss | (16,068 | ) | (4,462 | ) | (51,767 | ) | (46,570 | ) | ||||||||
| Cumulative dividends on class B and C preference shares | — | (2,073 | ) | — | (6,006 | ) | ||||||||||
| Net loss attributable to common shareholders | (16,068 | ) | (6,535 | ) | (51,767 | ) | (52,576 | ) | ||||||||
| Net loss per common share, basic and diluted | $ | (0.56 | ) | $ | (36.88 | ) | $ | (1.80 | ) | $ | (296.70 | ) | ||||
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 28,815,267 | 177,200 | 28,815,267 | 177,200 | ||||||||||||
| Other comprehensive loss | ||||||||||||||||
| Net loss | (16,068 | ) | (4,462 | ) | (51,767 | ) | (46,570 | ) | ||||||||
| Foreign currency translation | (4,696 | ) | (681 | ) | (11,722 | ) | (1,256 | ) | ||||||||
| Total comprehensive loss | (20,764 | ) | (5,143 | ) | (63,489 | ) | (47,826 | ) | ||||||||
IO BIOTECH, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(unaudited)
| September 30, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 151,168 | $ | 211,531 | ||||
| Prepaid expenses and other current assets | 6,554 | 10,207 | ||||||
| Total current assets | 157,722 | 221,738 | ||||||
| Restricted cash | 268 | 268 | ||||||
| Property and equipment, net | 464 | 155 | ||||||
| Right of use lease asset | 2,628 | — | ||||||
| Noncurrent assets | 887 | 127 | ||||||
| Total assets | $ | 161,969 | $ | 222,288 | ||||
| Liabilities, convertible preference shares and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,769 | $ | 3,928 | ||||
| Lease liability - current | 461 | — | ||||||
| Accrued expenses and other current liabilities | 3,498 | 6,377 | ||||||
| Total current liabilities | 5,728 | 10,305 | ||||||
| Lease liability - noncurrent | 2,394 | — | ||||||
| Other long-term liabilities | — | 59 | ||||||
| Total liabilities | 8,122 | 10,364 | ||||||
| Convertible preference shares | — | — | ||||||
| Stockholders’ equity | ||||||||
| Preferred stock, par value of | — | — | ||||||
| Common stock, par value of | 29 | 29 | ||||||
| Additional paid-in capital | 325,077 | 319,665 | ||||||
| Accumulated deficit | (158,048 | ) | (106,281 | ) | ||||
| Accumulated other comprehensive loss | (13,211 | ) | (1,489 | ) | ||||
| Total stockholders’ equity | 153,847 | 211,924 | ||||||
| Total liabilities, convertible preference shares and stockholders’ equity | $ | 161,969 | $ | 222,288 | ||||
FAQ
What are the recent developments for IOBT in clinical trials?
What are the latest results from IO Biotech’s Phase 1/2 study?
How much cash does IO Biotech have as of Q3 2022?
What were IO Biotech’s financial results for Q3 2022?
What is the expected timeline for data readouts from IO Biotech?
